Performance highlights on a constant exchange rate basis for the three months ended 30 September 2026 (Q3):

  • New business profit (NBP) was $709 million in Q3, up 1 per cent, leading to year-to-date NBP of $2,093 million, up 6 per cent.
  • Continued focus on quality contributed to a 3 percentage point year-to-date increase in new business margin.
  • We offset lower sales volumes from our Chinese Mainland life operations through strong growth in other markets, notably through the bancassurance channel.
  • Excluding our Chinese Mainland life operations, NBP grew by 13 per cent in Q3, and 11 per cent year to date.

Commenting on the results, CEO Anil Wadhwani said: “The benefits of growing diversification in our business model together with investment to build distribution capabilities were evident in the third quarter, with strong performance in many areas of our business, notably through the bancassurance channel, our Hong Kong domestic business, Thailand and Malaysia. The Group’s new business profit increased 1 per cent to $709 million in Q3, a resilient performance despite recent regulatory changes to bancassurance expense controls  and a strong prior year comparator, both in our Chinese Mainland life operations. Q3 new business profit growth, excluding our Chinese Mainland life operations, was 13 per cent. Overall, Group new business profit for the nine months to 30 September grew 6 per cent, with new business margin expansion of 3 percentage points supported by repricing.

“Outside of the Chinese Mainland, our bancassurance channel continued to deliver strong new business profit growth, in excess of 20 per cent in Q3. This was led by strong wealth demand in Hong Kong and successful new product launches in Thailand. Group bancassurance and agency channel new business profit grew by 10 per cent and 2 per cent year to date, respectively. We continue to enhance agent productivity through the roll out of enhanced digital tools, product propositions and quality recruitment programmes.

“Encouragingly, in both September and October, we have seen strong momentum in new business profit at a Group level, including in our Chinese Mainland life operations, albeit that the delay in the rate of improvement in momentum in our Chinese Mainland life operations means that achievement of our Group 2026 new business profit growth guidance is now more stretching than anticipated at the time of the Half-Year 2026 Results.

“We nevertheless remain focused on delivery of our FY26 guidance of double-digit growth across our four Key Financial Metrics, building on the strong first-half performance for operating free surplus generated from in-force insurance and asset management business and earnings-per-share based on adjusted operating profit and on achieving our 2027 financial objectives.”

APE new business sales (APE sales) and TEV new business profit (NBP)

Market highlights for the three months ended 30 September 2026

(New business profit and APE sales are both on a constant currency basis. See “Definitions of Performance Metrics” below for more details.)

In Hong Kong, continued focus on quality, together with repricing actions, supported double-digit growth in new business profit in Q3, notwithstanding lower sales volumes. Performance continued to be driven by higher margins and volumes in the bancassurance channel with strong demand from domestic customers. This was tempered by a slower conversion of the sales pipeline from some Chinese Mainland visitor customers. Overall, year-to-date new business profit was up double-digit when compared with the same period in the prior year, and we expect double-digit growth for the full year. This performance gives us confidence that the fundamental drivers of demand have not changed, albeit we continue to monitor Chinese Mainland visitor intentions to purchase insurance products.

As foreshadowed in our Half-Year 2026 Results, new business profit from our Chinese Mainland life operations, CITIC Prudential Life, declined significantly in the third quarter as sales volumes were constrained by recent changes to expense regulations in the bancassurance channel, with the rate of decline further exacerbated by the high comparator from July and August 2025. New business profit margin in Q3 exceeded 40 per cent with the overall margin for the nine months ended 30 September being 35 per cent. We delivered strong APE sales growth in the months of September and October which supports our confidence that, barring unforeseen events, the last quarter of 2026 will return to growth, albeit the rate of recovery will be slower than previously anticipated. Reflecting this, we expect that FY26 new business profit in the Chinese Mainland will be in the order of 10 to 15 per cent lower than 2025. This having been said, we believe that the change in bancassurance expenses regulation in the Chinese Mainland together with the management actions we are taking will improve the medium to long-term growth prospects of the business.

In our key ASEAN markets: Malaysia continued to grow strongly, delivering another quarter of double-digit new business profit growth, albeit moderated, as expected, from the very strong performance seen in the first half. In particular, we delivered higher health and protection APE sales on the back of strong demand from the mass affluent segment. In Indonesia, growth in active agents and improved product mix helped new business profit grow in September, but lower agency sales volumes in July and August meant that the total new business profit for Q3 was marginally below the prior year. Local investment conditions remain volatile given stock market turmoil and we are monitoring the impact on customer sentiment following the announcement from MSCI on 15 October 2026 that it was consulting on a proposal to reclassify its Indonesia Indexes from ‘Emerging Market’ to ‘Standalone Market’. Our Singapore new business profit in Q3 reduced slightly, with the impact of lower APE sales volumes partially offset by improved margins as our savings mix moved more towards investment linked business. We continue to broaden our health and protection offering, with two new product launches since September as we seek to return to growth in new business profit in the fourth quarter.

Our “Growth markets and other” segment delivered double-digit growth in new business profit in the third quarter, improving on the 10 per cent delivered in the first half of the year. New business profit growth was led by continued strong performance in Thailand as well as growth in Taiwan. Vietnam returned to growth in both sales and new business profit in the third quarter when compared to the same period in 2025.

In India we are making good progress with the necessary regulatory approvals for our announced acquisition of a controlling interest in Bharti Life and have successfully launched our standalone health business.

On 26 October, we strengthened the leadership team welcoming Naveed Irshad as an additional regional CEO and member of the Group Executive Committee. Naveed joins us from Manulife with over three decades of insurance and financial services experience across Asia and North America and takes responsibility for Indonesia, Philippines and Africa as well as Product and the Health pillar on a Group wide basis.